JPS52111555A - Novel anthracycline glycoside - Google Patents

Novel anthracycline glycoside

Info

Publication number
JPS52111555A
JPS52111555A JP252277A JP252277A JPS52111555A JP S52111555 A JPS52111555 A JP S52111555A JP 252277 A JP252277 A JP 252277A JP 252277 A JP252277 A JP 252277A JP S52111555 A JPS52111555 A JP S52111555A
Authority
JP
Japan
Prior art keywords
anthracycline glycoside
novel anthracycline
novel
glycoside
anthracycline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP252277A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6133039B2 (enExample
Inventor
Gosarubuesu Mario
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPS52111555A publication Critical patent/JPS52111555A/ja
Publication of JPS6133039B2 publication Critical patent/JPS6133039B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP252277A 1976-01-16 1977-01-14 Novel anthracycline glycoside Granted JPS52111555A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES444380A ES444380A1 (es) 1976-01-16 1976-01-16 Un procedimiento para preparar derivados metalicos antraci- clinicos.

Publications (2)

Publication Number Publication Date
JPS52111555A true JPS52111555A (en) 1977-09-19
JPS6133039B2 JPS6133039B2 (enExample) 1986-07-31

Family

ID=8470743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP252277A Granted JPS52111555A (en) 1976-01-16 1977-01-14 Novel anthracycline glycoside

Country Status (29)

Country Link
US (1) US4138480A (enExample)
JP (1) JPS52111555A (enExample)
AR (1) AR218620A1 (enExample)
AT (1) AT349634B (enExample)
AU (1) AU513698B2 (enExample)
BE (1) BE850438A (enExample)
CA (1) CA1070680A (enExample)
CH (1) CH629219A5 (enExample)
DD (1) DD129452A5 (enExample)
DE (1) DE2701405C2 (enExample)
DK (1) DK11877A (enExample)
EG (1) EG12735A (enExample)
ES (1) ES444380A1 (enExample)
FI (1) FI770115A7 (enExample)
FR (1) FR2338285A1 (enExample)
GB (1) GB1568263A (enExample)
GR (1) GR70696B (enExample)
HU (1) HU177832B (enExample)
IE (1) IE44689B1 (enExample)
IL (1) IL51264A (enExample)
NL (1) NL7700379A (enExample)
NO (1) NO770122L (enExample)
NZ (1) NZ183084A (enExample)
PH (1) PH16582A (enExample)
PL (1) PL108660B1 (enExample)
PT (1) PT66067B (enExample)
SE (1) SE7700398L (enExample)
SU (1) SU886748A3 (enExample)
YU (1) YU5477A (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959798A (en) * 1958-03-24 1960-11-15 Champlin Oil & Refining Co Pipe line cleaner
US4337335A (en) * 1978-05-18 1982-06-29 Schering Corporation Transition metal salt complexes of polyamino organic compounds
IT1184161B (it) * 1985-03-14 1987-10-22 Franco Conti Derivati del chitosano costituiti da complessi di coordinazione con ioni ferrosi
JPS63310830A (ja) * 1987-06-10 1988-12-19 Meiji Seika Kaisha Ltd 抗レトロウイルス剤
GB9613182D0 (en) * 1996-06-24 1996-08-28 Nycomed Imaging As Method
NL1009226C2 (nl) * 1998-05-20 1999-11-24 Faculteit Geneeskunde Universi Toepassing van een nucleïnezuur-bindend chemotherapeutisch agens, een farmaceutisch preparaat en een geneesmiddelcombinatie.
WO2004087097A2 (en) * 2003-03-31 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
US7053191B2 (en) * 2003-05-21 2006-05-30 Solux Corporation Method of preparing 4-R-substituted 4-demethoxydaunorubicin
AU2005303389A1 (en) * 2004-11-15 2006-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination therapy associating preferably a ceramide with a cytotoxic drug
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
EP3327148B1 (en) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
ES2768344T3 (es) 2011-06-17 2020-06-22 Myriad Genetics Inc Métodos y materiales para evaluar el desequilibrio alélico
JP6325453B2 (ja) 2011-12-21 2018-05-16 ミリアド・ジェネティックス・インコーポレイテッド ヘテロ接合性の消失(lossofheterozygosity)を評価するための方法および材料
ES2687024T3 (es) 2012-02-23 2018-10-23 Children's Medical Center Corporation Procedimientos para predecir la respuesta contra el cáncer
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
DK2981624T3 (da) 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
CA2931181C (en) 2013-12-09 2023-01-24 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
DK3686288T3 (da) 2014-08-15 2023-05-22 Myriad Genetics Inc Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3074927A (en) * 1960-04-12 1963-01-22 Paul D Saltman Metallic complexes of reducing sugars
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1469430A (en) * 1974-12-24 1977-04-06 Farmaceutici Italia Daunomycin derivatives

Also Published As

Publication number Publication date
DE2701405A1 (de) 1977-07-21
DE2701405C2 (de) 1986-02-27
JPS6133039B2 (enExample) 1986-07-31
PL108660B1 (en) 1980-04-30
EG12735A (en) 1981-03-31
FI770115A7 (enExample) 1977-07-17
IE44689L (en) 1977-07-16
DK11877A (da) 1977-07-17
CH629219A5 (de) 1982-04-15
NL7700379A (nl) 1977-07-19
HU177832B (en) 1981-12-28
PT66067B (en) 1978-06-23
IL51264A0 (en) 1977-03-31
NO770122L (no) 1977-07-19
DD129452A5 (de) 1978-01-18
AT349634B (de) 1979-04-10
GR70696B (enExample) 1982-12-30
PH16582A (en) 1983-11-22
SU886748A3 (ru) 1981-11-30
IL51264A (en) 1980-05-30
PT66067A (en) 1977-02-01
YU5477A (en) 1982-06-30
FR2338285B1 (enExample) 1980-03-14
CA1070680A (en) 1980-01-29
FR2338285A1 (fr) 1977-08-12
NZ183084A (en) 1980-04-28
AR218620A1 (es) 1980-06-30
PL195344A1 (pl) 1978-08-14
ES444380A1 (es) 1977-06-16
US4138480A (en) 1979-02-06
ATA19677A (de) 1978-09-15
AU513698B2 (en) 1980-12-18
GB1568263A (en) 1980-05-29
BE850438A (fr) 1977-05-16
IE44689B1 (en) 1982-02-24
AU2131977A (en) 1978-07-20
SE7700398L (sv) 1977-07-17

Similar Documents

Publication Publication Date Title
AU504480B2 (en) Anthracycline glycosides
AU500439B2 (en) Anthracycline glycosides
AU3560578A (en) Anthracyclines
AU513698B2 (en) Anthracycline glycosides
CY1161A (en) Anthracycline antibiotic compounds
PH14874A (en) Anthracycline derivatives
AU512372B2 (en) Anthracycline glycoside antibiotics
NZ186047A (en) Anthracycline glycosides
AU3560678A (en) Anthracyclines
GB1542162A (en) Anthracycline ethers
NZ185678A (en) Anthracycline disaccharide derivatives
GB2021571B (en) Anthracycline glycosides
NZ186048A (en) Anthracycline glycosides
ZA774148B (en) Anthracyclines
GB2021572B (en) Anthracycline glycosides
GB2034707B (en) anthracycline glycosides
JPS55124796A (en) Antitumor glycoside
GB1542163A (en) Anthracyclinones